For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220616:nRSP0563Pa&default-theme=true
RNS Number : 0563P Arecor Therapeutics PLC 16 June 2022
Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR ANNOUNCES EXCLUSIVE COLLABORATION WITH A TOP 5 GLOBAL PHARMACEUTICAL
COMPANY
Development of stable injectable high concentration formulations for its
proprietary products
Cambridge, UK, 16 June 2022: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
today announces that it has signed an exclusive formulation study
collaboration with a top five global pharmaceutical company.
Under the terms of the agreement, Arecor will use its proprietary formulation
technology platform, Arestat™, to develop improved, stable, high
concentration liquid formulations of its proprietary products. The Company
will fund the initial development work and has the option to acquire the
rights to the new proprietary formulations and associated intellectual
property under a technology licensing model.
Sarah Howell, Chief Executive Officer of Arecor, said: "This collaboration
expands our partner portfolio of high-profile pharmaceutical companies. The
growing recognition of how the Arestat™ platform can enhance a broad range
of therapeutic products is testament to our expertise and innovation in
formulation science. For our partners, we are able to significantly improve
their products to enable patient friendly treatment regimens that are
effective, safe and more convenient, which in turn can lead to better
adherence and health outcomes, benefitting healthcare systems as a whole."
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com (http://www.arecor.com/)
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD and Broker) Tel: +44 (0) 20 7886 2500
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Gray Tel: +44 (0) 20 3709 5700
Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
(http://www.arecor.com)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCFAMLTMTBBBJT